Physician profile
Bianca Mitchell
NPI 1447081807
$1,622.17
in general payments reported to CMS, 2019-2025
14 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $375 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $351.18 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $256.56 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.89 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $239.33 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $201.21 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Supernus Pharmaceuticals, INC. | $88.19 | 2025 | Qelbree |
| Lundbeck LLC | $49.32 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $47.43 | 2025 | Trintellix |
| Neurocrine Biosciences, INC. | $35.81 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.26 | 2025 | Cobenfy |
| Tris Pharma INC | $19.55 | 2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $18.55 | 2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $16.34 | 2024 | Spravato |
| Almatica Pharma LLC | $14.55 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.